Program
frexalimab
Also written as “Frexalimab”, “SAR441344 IV” and “SAR441344 SC”.
In Sanofi's pipeline, CD40L mAb
. Its studies are mostly in Multiple Sclerosis · Glomerulosclerosis, Focal Segmental · Diabetes Mellitus, Type 1 · Lupus Erythematosus, Systemic · Sjogren's Syndrome, led by Sanofi.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Sanofi | 119 open or running | phase 3since Nov 9, 2023 | Sep 28, 2020 | Dec 23, 2026phase 2 · NCT06500702 |
- Named in Sanofi’s own pipeline as
frexalimab
, phase 3, as of Sep 30, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Sep 28, 2020First study: phase 2 study in Sjogren's SyndromeFirst studyNCT04572841 · 84 enrolled · United States, Argentina, Belgium and more
- May 6, 2021Phase 2 study in Multiple SclerosisNCT04879628 · 129 enrolled · United States, Bulgaria, Canada and more
- Sep 1, 2021Phase 2 study in Lupus Erythematosus, SystemicNCT05039840 · 109 enrolled · United States, Argentina, Brazil and more
- Apr 26, 2023Phase 1 study in Healthy VolunteersNCT05845996 · 56 enrolled · United States
- Oct 27, 2023Phase 2 study in Diabetes Mellitus, Type 1NCT06111586 · 197 enrolled · United States, Austria, Belgium and more
- Nov 9, 20232 phase 3 studies in Multiple SclerosisNCT06141486, NCT06141473
- Jul 8, 2024Phase 2 study in Glomerulosclerosis, Focal SegmentalNCT06500702 · 84 planned · United States, Argentina, Australia and more
- Dec 23, 2025Phase 3 study in Multiple SclerosisNCT07325292 · 160 planned · United States, Belgium, Brazil and more
- Feb 3, 2026Phase 3 study in Kidney Transplant RejectionNCT07412470 · 526 planned · United States, Argentina, Australia and more
- Nov 3, 2026Phase 3 study in Multiple SclerosisNCT07930624 · 2,500 planned
Ahead
- Dec 23, 2026Primary completion: phase 2 study in Glomerulosclerosis, Focal SegmentalNCT06500702
- Apr 28, 2027Primary completion: phase 2 study in Diabetes Mellitus, Type 1NCT06111586
- May 6, 2027Primary completion: phase 3 study in Multiple SclerosisNCT06141473
- Jul 15, 2027Primary completion: phase 3 study in Multiple SclerosisNCT07325292
TargetBeta
“CD40L mAb”the company's pipeline, read by Claude · source
“A Randomized, Double-blind, Placebo-controlled, Multi-center Phase 2b Study With a Blinded Extension and an Optional Open-label Extension-Assessing the Safety and Efficacy of Frexalimab, a CD40L-antagonist Monoclonal Antibody, for the Preservation of Pancreatic β-cell Function in Adults and Adole…”study text, read by Claude · the study
Other programs on CD40LG
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| dazodalibeprule | Amgen | phase 3 | 9 |
| dapirolizumab pegolrule | UCB | phase 3 | 8 |
| tegoprubartrule | eledon-pharmaceuticals | phase 3 | 8 |
| ravagalimabrule | AbbVie | phase 2 | 4 |
| OPT101rule | op-t-llc | phase 2 | 4 |
| TNX-1500rule | Tonix Pharmaceuticals | phase 1 | 1 |
Studies
All 11 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07930624Multiple Sclerosis | 3 | Not yet recruiting | May 16, 2031 | 2,500 |
| NCT07412470Kidney Transplant Rejection · United States, Argentina, Australia and more | 3 | Recruiting | Aug 15, 2029 | 526 |
| NCT07325292Multiple Sclerosis · United States, Belgium, Brazil and more | 3 | Recruiting | Jul 15, 2027 | 160 |
| NCT06500702Glomerulosclerosis, Focal Segmental · United States, Argentina, Australia and more | 2 | Recruiting | Dec 23, 2026 | 84 |
| NCT06141486Multiple Sclerosis · United States, Argentina, Australia and more | 3 | Active, not recruiting | Mar 24, 2028 | 943 |
| NCT06141473Multiple Sclerosis · United States, Argentina, Austria and more | 3 | Active, not recruiting | May 6, 2027 | 1,655 |
| NCT06111586Diabetes Mellitus, Type 1 · United States, Austria, Belgium and more | 2 | Active, not recruiting | Apr 28, 2027 | 197 |
| NCT05845996Healthy Volunteers · United States | 1 | Completed | Apr 10, 2020 | 56 |
| NCT05039840Lupus Erythematosus, Systemic · United States, Argentina, Brazil and more | 2 | Active, not recruiting | Sep 4, 2026 | 109 |
| NCT04879628Multiple Sclerosis · United States, Bulgaria, Canada and more | 2 | Active, not recruiting | Sep 21, 2022 | 129 |
| NCT04572841Sjogren's Syndrome · United States, Argentina, Belgium and more | 2 | Completed | Nov 8, 2023 | 84 |
How it is read
Names in the registry
- “Frexalimab”, 9 entries
- “SAR441344 IV”, 2 entries
- “SAR441344 SC”, 2 entries
- “SAR441344”, 2 entries
- “frexalimab”, 1 entry
Conditions, from the studies’ own filings
- Multiple Sclerosis, 5 studies
- Glomerulosclerosis, Focal Segmental, 1 study
- Diabetes Mellitus, Type 1, 1 study
- Lupus Erythematosus, Systemic, 1 study
- Sjogren's Syndrome, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.